NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models
Autor: | Ping Zhang, Julie Marill, Sébastien Paris, Audrey Darmon, Bo Lu, Naeemunnisa Mohamed Anesary |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_treatment
Pharmaceutical Science Nanoparticle 02 engineering and technology 01 natural sciences International Journal of Nanomedicine Neoplasms Drug Discovery Tissue Distribution Original Research nanoparticle Oxides General Medicine 021001 nanoscience & nanotechnology Combined Modality Therapy Endocytosis Treatment Outcome 0210 nano-technology medicine.drug Biophysics Mice Nude Bioengineering Antineoplastic Agents 010402 general chemistry Hafnium oxide Biomaterials Cell Line Tumor medicine Animals Humans NBTXR3 cancer radioenhancer Mode of action radiotherapy Cell Proliferation Cisplatin business.industry Organic Chemistry Cancer medicine.disease 0104 chemical sciences Radiation therapy Cancer cell Cancer research Nanoparticles business Chemoradiotherapy Hafnium |
Zdroj: | International Journal of Nanomedicine |
ISSN: | 1178-2013 |
Popis: | Ping Zhang,1 Julie Marill,1 Audrey Darmon,1 Naeemunnisa Mohamed Anesary,1 Bo Lu,2 Sébastien Paris1 1Nanobiotix, Paris, France; 2Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, 19107, USACorrespondence: Sébastien ParisNanobiotix, 60 rue de Wattignies, Paris, 75012, FranceTel +33 1 75 44 72 33Fax +33 1 40 26 04 44Email sebastien.paris@nanobiotix.comPurpose: The side effects of radiotherapy induced on healthy tissue limit its use. To overcome this issue and fully exploit the potential of radiotherapy to treat cancers, the first-in-class radioenhancer NBTXR3 (functionalized hafnium oxide nanoparticles) has been designed to amplify the effects of radiotherapy.Patients and Methods: Thanks to its physical mode of action, NBTXR3 has the potential to be used to treat any type of solid tumor. Here we demonstrate that NBTXR3 can be used to treat a wide variety of solid cancers. For this, we evaluated different parameters on a large panel of human cancer models, such as nanoparticle endocytosis, in vitro cell death induction, dispersion, and retention of NBTXR3 in the tumor tissue and tumor growth control.Results: Whatever the model considered, we show that NBTXR3 was internalized by cancer cells and persisted within the tumors throughout radiotherapy treatment. NBTXR3 activated by radiotherapy was also more effective in destroying cancer cells and in controlling tumor growth than radiotherapy alone. Beyond the effects of NBTXR3 as single agent, we show that the antitumor efficacy of cisplatin-based chemoradiotherapy treatment was improved when combined with NBTXR3.Conclusion: These data support that NBTXR3 could be universally used to treat solid cancers when radiotherapy is indicated, opening promising new therapeutic perspectives of treatment for the benefit of many patients.Keywords: radiotherapy, radioenhancer, nanoparticle, NBTXR3, cancer |
Databáze: | OpenAIRE |
Externí odkaz: |